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Abstract  
Subfertility is common, and affects one in six couples, half of whom lack an explanation for their delay in 
conceiving. Developments in the diagnosis and treatment of subfertility over the past 50 years have been 
truly remarkable. Indeed, current generations of couples with subfertility are more fortunate than 
previous generations as they have many more opportunities to become parents. The timely access to 
effective treatment for subfertility is important, as many couples have a narrow window of opportunity 
before the age-related effects of subfertility limit the likelihood of success. Assisted reproduction can 
overcome the barriers to fertility caused by tubal disease and low sperm counts, but little progress has 
been made in reducing the effect of increasing age on ovarian function. The next 5-10 years will likely see 
further increases in birth rates in women with subfertility, greater awareness of lifestyle factors and 
possible refinement of current assisted reproduction techniques and development of new ones. Such 
progress will bring challenging questions regarding the potential benefits and harms of treatments 
involving germ-cell manipulation, artificial gametes, genetic screening of embryos, and gene editing of 
embryos. We hope to see a major increase in fertility awareness, access to safe and cost-effective fertility 
care in low-income countries, and a reduction in the current disparity of access to fertility care. 
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 [H1] Introduction  
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Subfertility (also commonly referred to as infertility) is defined as “a disease characterised by the failure 
to establish a clinical pregnancy after 12 months of regular, unprotected sexual intercourse or due to an 
impairment of a person’s capacity to reproduce either as an individual or with his/her partner”. A clinical 
pregnancy is defined as “ultrasonographic visualization of one or more gestational sacs or definitive 
clinical signs of pregnancy”. Both of these comprehensive definitions were reached through a consensus 
process at the World Health Organization (WHO), and were subsequently supported by regional fertility 
societies and international professional societies that address fertility care and infertility  1, 2. Primary 
female subfertility refers to a woman who has never achieved a clinical pregnancy, whereas secondary 
female subfertility refers to a woman who has previously achieved a clinical pregnancy who cannot 
establish a subsequent clinical pregnancy.1,2 The definitions cited above are clinical definitions, designed 
for the early detection and treatment of subfertility. Other definitions are used for demographic or 
epidemiological purposes. For example, an alternative definition of primary subfertility is the inability to 
ever bear a live child, and an alternative definition of secondary subfertility is the inability to bear a live 
following a previous pregnancy or live birth 3, 4 
 
Several critical steps are in achieving unassisted pregnancy in women. Follicular development leading to 
oocyte release from the ovary requires a normal menstrual cycle, which is coordinated by a complex 
interplay of pituitary and follicle-derived hormones. After an oocyte is released, it enters the fallopian 
tube where it can be fertilised by spermatozoa (sperm) that have travelled through the female genital 
tract (Figure 1). The fertilised oocyte develops as it moves though the fallopian tube into the uterine 
cavity, where it implants in the endometrium. In women, subfertility can involve any of these processes, 
whereas in men, subfertility centres around absent or inadequate sperm production (Box 1). 
 
Common causes of female subfertility include ovulatory dysfunction (such as ovarian insufficiency or 
polycystic ovary syndrome (PCOS)), damaged or blocked fallopian tubes, endometriosis and uterine 
fibroids. Ovarian insufficiency is a loss of function of the ovaries that reduces the chance of pregnancy in 
all women from ~35 years of age, but occurs prematurely in some women. Blocked or damaged fallopian 
tubes can cause subfertility or an increased risk of tubal pregnancy  5, 6. Endometriosis can create an 
unfavourable pelvic environment, whereas uterine fibroids can impede tubal transport, cause tubal 
obstruction or affect embryo implantation, both of which can lead to subfertility in women. In up to 30% 
of couples, no identifiable cause of subfertility can be found after completion of a standard investigation 
protocol and tests of ovulation, tubal patency and semen analysis, among others, are normal 7. These 
cases are commonly referred to as ‘'unexplained’ subfertility in the literature; in this Primer, we retain 
this term for consistency with the literature, but with the proviso that ‘unexplained’ does not mean that 
subfertility has no underlying cause, rather that the cause has not been identified.  
 
Over the last 20 years there has been a move towards evidence-based, cost effective and safer fertility 
treatment. In addition, there is a general recognition by clinicians that subfertility differs from many other 
health conditions that are diagnosed on the basis of demonstrable pathology. As a consequence, 
management strategies are appropriately moving away from a traditional aetiological approach towards a 
prognostic approach, in which the decision to treat is based on the balance between the unassisted and 
treatment-related chances of pregnancy. However, the physical, psychological and financial burden of 
treatment can be substantial. Timely access to effective treatment is important, as many couples have a 
narrow window of opportunity before age limits the likelihood of success. 
 
This Primer reviews the epidemiology, pathophysiology, assessment and clinical and psychosocial 
management of subfertility in women and considers priorities for future research. 
 
[H1] Epidemiology  
 
Up to one in six couples in Western countries have subfertility  8 and is a recognised cause of 
psychological distress in both men and women  9. Between 48.5 and 72.4 million couples worldwide are 
estimated to have subfertility 3, 10 , with 10 million couples in Sub-Saharan Africa and 14 million couples in 
South Asia  3.  The prevalence of subfertility varies widely between studies owing to variability in the 
populations sampled and inconsistency in the definition of subfertility  11 and sampling methods 
used.  Clinical definitions of subfertility that are based on lack of pregnancy after 12 months of 
unprotected sexual intercourse estimate a median prevalence of 9% globally  10, although demographic 
definitions that are based on a 5 year period of childlessness (Figure 2) estimate rates of primary 
infertility as ~2% and secondary infertility of ~10% 3. 
 3 
  
Couples are typically referred for fertility investigations if they have not been able to conceive within 12 
months of sexual intercourse without using contraception. Although some couples might equate their 
condition of subfertility with sterility, this is an oversimplification as many will subsequently conceive  12. 
The definition of subfertility is prognosis-driven and is based on data demonstrating that 84% of couples 
not using contraception would be expected to conceive within one year and 92% within two years 13. 
However, to be meaningful, a prognosis-based approach should accommodate factors other than duration 
of subfertility, such as female age, frequency of intercourse, semen quality and the presence of pelvic 
pathology that could influence the chance of conception 14. Ideally a model would also include psychological 
and lifestyle factors that affect fertility either directly or indirectly 15. 
Few studies have examined long term trends in subfertility. Although the demand for ART has risen 
steadily over the last 20-30 years  16, this trend does not seem to be accompanied by a corresponding 
increase in the observed prevalence of subfertility 17, 18 Some of the reasons for increase in demand for 
ART are expanding indications for the IVF treatment such as unexplained infertility and diminished 
ovarian reserve, increased access to more patient friendly IVF program and appeal of newer technologies.  
 
[H2] Risk factors 
[H3] Lifestyle factors. In observational studies, lifestyle factors such as smoking, excessive alcohol 
consumption and caffeine use have been associated with reduced fertility  19, 20. A case-control study in the 
United Kingdom identified negative lifestyle factors significantly associated with current subfertility, 
including overweight (by >13 kg), unprotected sexual intercourse with multiple partners and ‘stress one 
cannot cope with’ 19. Cigarette smoking and marijuana use were significantly associated with increased 
time to conceive 20. However, prospective research is needed to confirm these cross-sectional 
associations. Occupations involving exposure to reproductive toxins that can affect fertility such as 
nitrosamines and formaldehyde should be documented 21. 
 
[H3] Age. One of the best-known and most well-established factors that affect fertility is the age of the 
woman (Figure 3) 22. This risk factor is increasingly relevant as women worldwide delay childbearing and 
as the age at which a woman has her first child is rising in many societies  23. In addition, the fertility rate 
(that is, the total number of children that would be born to each woman if she were to live to the end of 
her child-bearing years), has also fallen substantially  24. For women, the likelihood of pregnancy is stable 
from puberty to ~30 years of age, after which, it declines in an accelerating rate until menopause when 
the chance of pregnancy approaches zero 25-27.  
 
[H1] Mechanisms/pathophysiology  
Unlike many other conditions, subfertility involves two individuals (or three, in the case of donor gametes 
or surrogacy). An individual might experience subfertility with one partner but not with another, and 
with increasing age, all women have infertility secondary to the complete loss of oocytes. By contrast, 
men continue to produce viable sperm throughout their life.  
 
 A key concept is the chance of achieving pregnancy in a specific ovulatory cycle at any given point in 
time; in contrast to other species in whom chances of conceiving are close to 100% during every 
menstrual cycle, in humans, even at their most fertile stages of life, changes of conceiving are, at most, 
30% in a menstrual cycle 28 presumably secondary to the short window of oocyte maturation in the 
human oocyte. Accordingly, distinguishing whether the absence of pregnancy in a single cycle is due to 
natural reproductive inefficiency or the result of a specific pathophysiological situation that requires 
treatment is often difficult. Likewise, decisions about treatment of subfertility should be made after 
considering the chance of establishing a pregnancy without treatment (see Management) 12 
 
 [H2] Age and oocyte quality  
Ovarian age is a strong predictor of the chance of pregnancy and reflects the number of follicles still 
present in the ovary. At birth, girls have ~2 million oocytes in their ovaries, of which more than half are 
lost before puberty .Following the onset of ovulation, a cohort of 40-500 follicles develop each month of 
which, usually only one (the so-called dominant follicle) releases an oocyte 29. The other follicles 
degenerate, and are ultimately lost through the process of follicular atresia. The number and quality of 
remaining oocytes reduces with increasing age (Figure 3)  25, leading to the age-related decline in female 
fertility. Estimation of the number of follicles inside the ovaries (that is, ovarian reserve) is possible using 
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ultrasonography to measure the antral follicle count (AFC) or by measurement of the serum anti-
müllerian hormone (AMH) level  27, 30, 31. 
 
Recruitment and maturation of follicles in the ovary is a balanced interaction between hormones released 
by the hypothalamus and pituitary gland (such as follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH)), and those released in the ovary (AMH, inhibin A and inhibin B and estradiol) 27. As these 
ovarian factors are produced by the granulosa cells of the antral follicles, reduced ovarian reserve results 
in lower levels of these hormones. This change in turn results in higher FSH levels . These aberrant 
hormonal levels cause menstrual cycle irregularities and affect the quantity and quality of available 
oocytes.  
 
The effect of increased age on oocyte quality and chance of pregnancy is illustrated by pregnancy 
outcomes in women who receive oocytes from young donors 32; oocytes from young donors have a higher 
rate of subsequent pregnancy than oocytes from older donors, even if the recipient is undergoing 
menopause. No established intervention to prevent this age-related decline in fertility is available, except 
for the use of donor oocytes. 
 
The precise mechanism by which age affects oocyte quality is unknown. One hypothesis is an 
accumulation of DNA damage in the oocytes over time, through environmental stressors, for example by 
certain food or drug residues, or by reactive oxygen species (ROS) 33, 34. Alternatively, a first-in-first-out 
principle (also known as a production line principle) has been proposed, whereby high quality oocytes 
are primarily ovulated early in life, causing lower quality oocytes to be ovulated at later ages. This 
hypothesis is based the decrease in the frequency of chiasmata (the physical crossover of homologous 
chromosomes) in mouse oocytes with increasing maternal age 35, 36. These reductions could also explain 
the increased number of aneuploidies in oocytes, embryos and other products of conception in 
miscarriages in older women 37-39 . 
 
In addition, data from mouse models suggests that shortening of telomeres in oocytes is also associated 
with increasing age and could also cause decreased oocyte and embryo competence  40, 41. The female germ 
line could also be affected by general mechanisms underlying cellular aging, such as, epigenetic 
alterations, loss of proteostasis, dysregulated nutrient sensing, altered intercellular function, and 
mitochondrial dysfunction, which could contribute to subfertility  42, 43. As previously mentioned, the age-
dependent decline in oocyte quality accelerates between 35 and 40 years of age, suggesting that oocyte 
ageing is time limited rather than a gradual process. This finding suggests that an underlying biological 
threshold value or trigger is involved in oocyte ageing, for example, the number of primordial follicles 
dropping below a critical threshold, thereby triggering subtle physiological events, such as hormonal 
(such as growth hormone and androgens) changes. These hormonal changes could affect the oocytes 
themselves, the surrounding granulosa cells, the process of selection from the cohort of oocytes each 
menstrual cycle, and oocyte maturation.  
 
Oocyte quality can also affect development of the preimplantion embryo  44 . This is supported by the 
increased presence of aneuploidies in oocytes of women of advanced age (Figure 3). However, this age-
related increase in aneuploidies is likely to be a consequence of poor oocyte quality, rather than the 
cause. Oocyte quality also influences the embryonic and fetal development, as demonstrated by the 
increased risk of miscarriage in older women which can be reversed by the use of oocytes from young 
donors  46, 47.  
  
[H2] Specific causes of subfertility  
 
[H3] Ovulatory dysfunction. Anovulation (a failure to ovulate) is indicated by a disturbed frequency and 
duration of the menstrual cycle (Figure 4). Typically, the menstrual cycle is 25-35 days in duration, but 
some woman never menstruate (primary amenorrhea), some can menstruate but have prolonged episodes 
of >6 months without a period (secondary amenorrhea), or have an irregular menstrual cycle 
(oligomenorrhea).  
 
Primary amenorrhea can result from the failure of normal gonadal development or be unexplained. The 
failure of gonad development can be idiopathic, or can be associated with a wide range of conditions, 
including Turner Syndrome (in individuals with a 45, XO karyotype), hypothalamic problems secondary 
to a spectrum of disorders (such as extremes of body weight, chronic disease such as coeliac disease, or 
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high stress levels). Structural anatomical conditions, including imperforate hymen and the complete 
absence of the genital organs owing to the failure of normal gonadal development may also present as 
primary amenorrhoea.  
Secondary amenorrhoea and oligomenorrhea can be caused by endocrine disorders involving the 
hypothalamus, pituitary gland, thyroid gland, the adrenal gland and the ovary  48. The correction of 
thyroid function is required before any fertility treatment commences, as disorders of thyroid function 
are associated with problems in fetal development  48. Pituitary adenomas produce high levels of 
prolactin, which inhibits gonadotropin-releasing hormone secretion and the production of 
gonadotropins, which leads to suppression of ovulation. Rarely, anterior pituitary failure occurs following 
severe postpartum haemorrhage (known as Sheehan Syndrome) and may result in hypopituitarism with 
low levels of gonadotrophins, growth hormone, adrenocorticotrophin, thyroid stimulating hormone and 
prolactin. Replacement therapy will be necessary and when fertility is desired then ovarian stimulation 
with gonadotrophins can be given.  
The most-common cause of anovulation associated with oligomenorrhea and amenorrhea is polycystic 
ovary syndrome (PCOS)  49. The exact causes of PCOS are not known, but women with PCOS have an 
increased frequency of pulses of GnRH release from the hypothalamus, which increases the LH/ FSH ratio 
leading to higher androgen levels, hampered follicle maturation and possible anovulation  49. Although 
women with PCOS have high rates of subertility compared with women without PCOS, the majority do 
usually conceive with or without treatment 50. 
 
[H3] POF and POI. In some women, decreased ovarian reserve occurs prematurely and menopause is 
reached earlier, in some cases when women are teenagers, which is referred to as premature ovarian 
failure (POF) or primary ovarian insufficiency (POI).  
Causes of POF and POI include a low initial number of ovarian follicles,which can be idiopathic, or an 
abnormally high rate of follicular atresia (for example, Turner syndrome or fragile X syndrome) or can be 
caused by cytotoxic therapies. Some women with POI have a sufficient number of follicles but have 
specific genetic defects, enzyme deficiencies or specific autoimmune responses that affect follicular 
growth and maturation. In Turner syndrome, POF or POI is due to the accelerated loss of oocytes from the 
ovaries after the 18th week of fetal life or during the postnatal period 51. Fragile X syndrome is caused by 
an increase in the number of CGG trinucleotide repeats in FMR1 (encoding fragile X mental retardation 1 
protein) 52. Women with too many or too few CGG repeats in FMR1 have an increased risk of menstrual 
cycle disturbances, POF, non-identical twinning and possibly increased rates of aneuploidy and 
miscarriage 52. 
 
[H3] Ovarian cysts. Ovarian cysts are frequently detected because of the increased use of imaging such as 
ultrasonography and MRI. They range from simple cysts associated with the menstrual cycle (such as 
persistent follicular cysts) to cysts of endometriosis (endometriomata) or teratomas such as dermoid cysts. 
In women who are seeking to conceive, these cysts generally do not negatively impact on fertility unless 
they are large enough to distort tubal anatomy. Indications for removal of these cysts will depend on the 
symptoms and the benefits and harms of the surgery.  
 
[H3] Pelvic, uterine and tubal abnormalities. Tubal abnormalities range in severity from scarring and 
mild adhesions (fibrous bands between organs) to complete blockage or absence of the fallopian tubes. In 
some cases, the fallopian tube is blocked at least at the distal end and is filled with fluid (hydrosalpinx). 
Tubal abnormalities can be caused by infections (such as chlamydia, gonorrhea, and tuberculosis) often 
transmitted sexually, that cause scarring and damage of the tubal tissue, in addition to peritoneal infection, 
previous surgeries, or endometriosis, and rarely, genetic defects 53. Subfertility is common in women with 
HIV, and is usually associated with tubal blockage (most commonly hydrosalpinges) particularly in women 
with a history of induced abortions and tubal pathologies 54. Uterine abnormalities can be caused by uterine 
fibroids, polyps or adenomyosis, or congenital malformations. 
Endometriosis is a condition in which tissue from the lining of the uterine cavity grows outside the uterus 
into the peritoneal cavity . Endometriosis not only involves the fallopian tubes, but also will be present in 
the ovaries, and the tissue lining the pelvis which often leads to distorted and abnormal anatomy. This 
aberrantly located endometrial tissue is affected by the hormonal changes of the menstrual cycle, which 
makes it grow, thicken, and subsequently break down each cycle, which can lead to painful periods, heavy 
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menstrual bleeding or bleeding between periods. In addition, endometriosis causes subfertility, as the 
aberrant endometrial tissue can result in scar formations and adhesions. The severity of endometriosis 
depends on the number, size, location, and depth of the endometrial implants outside the uterus  55-57. 
Defects in the development of the Müllerian duct (which form the cervix, uterus, fallopian tubes and part 
of the vagina) can lead to abnormal development of these drugs and potentially subfertility. 
Approximately 1 in 4,500 women have Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, in which 
abnormal development of the Müllerian duct system results in the absence of the upper vagina, uterus 
and in some women, the fallopian tubes, but with intact ovaries and normal external genitalia  58. Genes 
that are involved in prenatal development are causative, but differ between individuals. More-subtle 
defects in Müllerian duct development can lead to a unicornuate uterus (only half of the uterus with a 
single fallopian tube is present), a bicornuate uterus (an indentation in the fundus of the uterus, leading 
to an approximately heart-shaped uterus), or a septate uterus (the uterine cavity is partly partitioned by 
a longitudinal septum). These congenital uterine malformations are of unknown cause. Women with 
these uterine malformations can be asymptomatic, can be unaware of having these conditions and can 
have normal pregnancies. Some uterine malformations are associated with an increased risk of recurrent 
pregnancy loss and preterm birth, but an association with subfertility is less clear 59-62. 
Other uterine abnormalities can be caused by fibroids, polyps or adenomyosis (in which endometrial 
tissue grows within the walls of the uterus). Although these conditions are often thought to be associated 
with a reduced chance of ongoing pregnancy because of miscarriage, there is no conclusive evidence that 
they adversely affect conception 63, 64. Rare uterine abnormalities can be congenital anomalies that are 
acquired through, for example, prenatal exposure to diethylstilbestrol or following surgery such as 
intrauterine adhesions with a thin endometrium (known as Asherman syndrome) and reduce the 
likelihood of implantation and ongoing pregnancy.  
 [H1] Diagnosis, screening and prevention  
 Few standard tests for the diagnosis of subfertility are available.  Geographical variation in the uptake 
and availability of investigations is likely, owing to the affordability of these tests. Moreover, practice 
guidelines vary, as shown by recommendations on PCOS and systematic reviews of diagnostic evaluation 
of male infertility and of endometriosis 65-67. 
 
[H2] Diagnosis 
In countries with fertility care provision, couples are generally investigated after 12 months of unsuccessful 
attempts to conceive, or earlier if there is a clear clinical indication 1. A comprehensive fertility assessment 
involves both partners and includes detailed history taking, clinical examination and appropriate 
investigations (Figure 5). The aim of this assessment is to identify underlying causes of subfertility and 
establish a prognosis for the couple 15, 68.  
 
[H3] Comprehensive history. A detailed history taking should document the length of time a couple has 
been trying to conceive, menstrual patterns, previous pregnancies, medical and surgical factors, lifestyle 
and family history. 
 
The age of menarche should be recorded, as an absence or delay in the onset of menarche could be 
associated with ovulatory dysfunction. Regular menstrual cycles are suggestive of ovulation, whereas 
irregular cycles and abnormal flow can be suggestive of hormonal, endometrial or uterine pathology. 
Dysmenorrhea (menstrual cramps), chronic or cyclical pelvic pain and dyspareunia (painful sexual 
intercourse) can indicate the presence of pelvic endometriosis, whereas pressure symptoms (for example 
on the bladder or other organs) can be indicative of uterine fibroids and ovarian cysts. Contraceptive 
history is important, as some hormonal methods (such as, combined oral contraceptives) can lead to a 
temporary disturbance in menstrual cyclicity 69, and a discussion of lifestyle is important, as some factors 
can affect fertility. 
 
Examining the medical and/or surgical treatment history and any associated infection of women with a 
history of miscarriage or abortion might be useful to identify potential causes of secondary subfertility. A 
history of ectopic pregnancy and salpingectomy (the surgical removal of a fallopian tube) is suggestive of 
tubal damage, whereas amenorrhoea associated with peri-partum or post-partum haemorrhage might be 
Commented [MOU6]:  
Alessandro ConfortiEmail author,  
Carlo Alviggi,  
Antonio Mollo,  
Giuseppe De Placido and  
Adam Magos 
The management of Asherman syndrome: a review of 
literature. Reproductive Biology and 
Endocrinology201311:118 
 
 7 
associated with either pituitary infarction or intrauterine adhesions (Asherman syndrome) due to vigorous 
dilatation and curettage.  
 
In addition, the presence of co-existing or previous medical conditions should be carefully evaluated. Any 
symptoms and signs of breast disease should be investigated and a cervical smear history sought. A history 
of gonadotoxic therapy for a malignant disorder or an autoimmune condition can affect ovarian reserve 70, 
whereas infectious diseases such as tuberculosis or HIV can be associated with pelvic inflammatory disease 
and subfertility 71, 72. Pelvic operations can result in adhesions leading to distorted pelvic anatomy, and can 
affect tubal function, whereas ovarian surgery, such as for endometriomas (endometriotic cysts), can 
compromise ovarian reserve.  
 
As previously mentioned, fertility can be affected by disorders such as PCOS, ovarian insufficiency and 
endometriosis, which can be familial; the identification of these disorders might require clinical assessment 
and appropriate genetic counseling. In some contexts, cultural practices such as female genital mutilation 
and consanguinity can be associated with fertility problems 73, 74. The occupation of both female and male 
partners should be documented and where relevant, risk of exposure to reproductive toxins should be 
assessed. 
 
[H3] Physical examination. A general physical examination includes evaluation of body mass index (BMI), 
blood pressure, for thyroid enlargement and general assessment of secondary sexual characteristics and 
hair distribution, and is useful for the diagnosis of hyperandrogenism, endocrinopathies and uterine, pelvic 
and ovarian abnormalities.  
 
Clinical signs of hyperandrogenism such as acne and hirsutism can suggest PCOS. The modified Ferriman 
Gallway score is used to assess hirsutism objectively and the score is interpreted in the context of the 
woman’s ethnicity. For example, for women from South East Asia, it is suggested to use a cut-off point lower 
than the conventionally agreed threshold, as these women have a lower density of facial terminal hair 75. 
Acanthosis nigricans, observed in women with PCOS, is characterized by hyperpigmented velvety skin 
patches on the back of the neck, axilla and inguinal creases 76. Androgen-secreting tumours such as tumours 
of the adrenal gland or ovaries lead to more pronounced signs of androgen excess compared with PCOS , 
characterized by features of virilization (masculine traits, such as severe acne, deepening of voice, male 
pattern baldness and clitoromegaly). Demonstrable galactorrhoea (milky discharge from breast unrelated 
to pregnancy or breastfeeding ) should trigger investigations to rule out a prolactinoma. 
 
Surgical scars suggest the type of previous surgery and can guide decisions about future diagnostic or 
therapeutic procedures. Clear swelling in the lower abdomen can indicate a large fibroid or ovarian cyst, 
which can be confirmed using radiographic imaging. External inspection of the genitalia followed by a 
speculum examination should be carried out to assess the cervix and rule out the presence of infection, 
cervical polyps and vaginal septum or double cervix which helps identify congenital uterine abnormalities 
such as uterine didelphys and bicornuate uterus. A high vaginal and chlamydial swab can be obtained at 
the same time as speculum examination to assess for infectious diseases. 
 
Transvaginal ultrasonography of the pelvis is an accurate way to visualize the uterus and ovaries and can 
identify ovarian cysts, endometriomas and hydrosalpinges, among other disorders. However, transvaginal 
ultrasonography should be used as an adjunct to, rather than a replacement for, bimanual pelvic 
examination. The latter remains the best way of assessing the position, consistency and mobility of large 
pelvic masses such as fibroids and ovarian cysts before surgery, whereas palpation of a retroverted fixed 
uterus and nodules in the pouch of Douglas (also known as the recto-uterine pouch) may be the only signs 
of deep infiltrating endometriosis 77. 
  
[H3]Ovulation tests. A history of regular menstrual cycles is suggestive of satisfactory ovulation in most 
women although a test to confirm ovulation such as a mid luteal phase progesterone is usually 
recommended. 78 Many women may choose to use regular menstrual diaries or fertility tracking software 
or applications to track ovulation 79. In terms of clinical tests of ovulation, serum mid luteal progesterone 
levels is considered the gold-standard, and is the most commonly used; the timing of this test is important, 
and samples should ideally be taken 7 days before the expected onset of the next menstrual period. 
Progesterone tracking (taking two or three samples over several days) can be helpful in women whose 
cycle length, although regular, can vary by a few days 80. Other diagnostic tests to assess ovulation include 
ultrasonography-based monitoring of a developing follicle and detection of an LH surge by means of serial 
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measurements of serum or urinary LH levels. Although the detection of secretory endometrium via 
endometrial biopsy is suggestive of ovulation, this procedure is invasive and requires correct timing, and 
is, therefore, no longer recommended in contemporary practice  80. 
 
The choice of ovulation test depends on patient preferences, and the cost and availability of resources to 
do these tests. Ultrasonography for the detection of ovulation relies on findings such as the detection of the 
collapse of a dominant follicle and has a sensitivity of 84% and a specificity of 89% for the confirmation of 
ovulation 81. One of the advantages of urinary LH estimation is that this allows self-testing, and has a 
concordance rate of around 90 - 97% with ultrasonography-detected ovulation 82, 83.  
 
In women with very irregular cycles, amenorrhoea or confirmed anovulation, measurement of serum levels 
of estradiol, FSH, LH, thyroid-stimulating hormone, testosterone and prolactin are warranted to identify 
the cause of anovulation. Anovulation can be classified as WHO Type I (or hypogonadotrophic 
hypogonadism), Type II (or normogonadotrophic) or Type III (hypergodanotrophic), based on serum 
gonadotrophin and estradiol levels (Table 1). PCOS is the most-frequent cause of anovulation in general, 
and Type II anovulation in particular, and is often associated with hyperandogenism. PCOS is defined by 
presence of two out of the three following features: oligo-ovulation or anovulation, clinical and/or 
biochemical signs of hyperandrogenism or polycystic ovaries detected using ultrasonography, after 
excluding other related disorders 84. Rarely, adrenal disorders or an androgen-producing tumour could 
cause ovulatory dysfunction associated with hyper-androgenism. In these cases, measures of 17-
hydroxyprogesterone, serum testosterone, androstenedione and dehydroepiandrosterone levels are 
advised to discriminate between ovarian and adrenal causes.  
 
[H3]Assessment of tubal patency. Tubal patency tests are used when initial tests confirm ovulation and, 
in male sexual partners, normal semen parameters. In women with anovulation, patency tests can be used 
prior to ovulation induction, or can be delayed until after three drug-induced ovulatory cycles. Tubal 
patency testing is generally considered unnecessary in couples who require ART to conceive either because 
of severe male factor infertility (for example, sperm count < 5 million/ ml) or women with advanced age 
because in ART the embryo is directly  placed into the uterine cavity, bypassing the fallopian tubes. Women 
with a recent intrauterine pregnancy loss do not require tubal patency testing, unless post-miscarriage 
infection is indicated.  
 
Commonly performed tubal patency tests include hysterosalpingography (HSG), 
hysterocontrastsalphingography (HyCoSy) and diagnostic laparoscopy with chromotubation. HSG involves 
the injection of water or oil-based radio opaque iodine dye through the cervix, under fluoroscopic guidance, 
and has a sensitivity of 53% and a specificity of 87% for tubal pathologies (46% and 95% for bilateral tubal 
pathologies, respectively) 85. HSG is useful in ruling out tubal blockage, but has limited diagnostic value for 
other tubal pathologies, such as peritubal adhesions 86. HyCoSy is less invasive than HSG and carries no risk 
of exposure to radiation, and involves the injection of a contrast fluid during a transvaginal 
ultrasonography to outline the uterine cavity and Fallopian tubes. HyCoSy has a sensitivity of 80% and a 
specificity of 84% for tubal pathology compared with laparoscopy  87. Although diagnostic laparoscopy and 
chromotubation is considered the gold standard for tubal patency assessment, this procedure is invasive 
and expensive. Laparoscopy and chromotubation is performed under general anaesthesia, allows direct 
visualization of the entire pelvis and facilitates the detection of, for example, endometriosis and pelvic 
adhesions (Figure 6). In addition, this procedure allows for surgical interventions such as treatment of 
endometriosis, adhesiolysis for pelvic adhesions or cannulation for tubal blockage (see Management). 
Complication occur at a rate of 0.6 per 1,000 laparoscopies and major risks include anaesthetic 
complications as well as blood vessel and bowel injury 88. 
 
The choice of tubal tests depends on the presence of risk factors, such as history of pelvic inflammatory 
disease, or clinical considerations such as BMI and previous abdominal surgery. Tubal patency tests should 
be scheduled immediately after menses (up to day 12) to avoid disruption of an early undetected 
pregnancy. These tests are invasive and are associated with risk of infection, therefore, chlamydia 
screening and prophylactic antibiotic administration where necessary are required.  
 
[H3]Assessment of uterine and peritoneal factors. All women with infertility are offered a transvaginal 
ultrasonography (TVS) if they have symptoms suggesting underlying pathology  77. TVS can detect uterine 
cavity abnormalities, fibroids and adenomyosis, allows visualization of the ovaries (to detect and assess 
ovarian cysts or endometriomas) and can be used to assess AFC. The accuracy of TVS for detecting 
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intrauterine lesions varies from 52.6% to 77.2%, but is ~90.6% for uterine malformations 89, 90. Saline 
infusion sonography (SIS, whereby saline is inserted into the uterine cavity to allow visualization of the 
intra cavitary pathologies) has a sensitivity of 0.88 and a specificity of 0.94 for detecting all intrauterine 
abnormalities 91. MRI is superior to ultrasonography for the detection of congenital malformations of the 
uterus and lower genital tract and might be useful to guide management of fibroids and recto-vaginal 
endometriosis 66, 92.  
Diagnostic hysteroscopy is the gold standard procedure for assessing the uterine cavity, and concurrent 
treatment can be provided for conditions such as endometrial polyps, uterine septum and intrauterine 
adhesions. The overall complication rate and risk of uterine perforation with diagnostic hysteroscopy is 
~0.28% and 0.13%, respectively  93. However, there is no evidence that routine hysteroscopy in women 
before assisted reproduction improves chances of conception  64, 94 
 
[H3]Tests for ovarian reserve.  
Ovarian reserve tests can be used to identify women with POF, and are used to identify women at high risk 
of compromised ovarian function due to increased age (>35 years of age), a family history of early 
menopause or previous gonadotoxic therapy or ovarian surgery. Tests of ovarian reserve are essentially 
tests of ovarian responsiveness to exogenous stimulation and can be useful for planning the dose of ovarian 
stimulation in women who intend to have ART 95. Common tests of ovarian reserve include levels of FSH, 
AMH and the AFC. Increased levels of serum FSH during the early follicular phase of the menstrual cycle 
are associated with reduced ovarian reserve. AMH is secreted by the granulosa cells of pre-antral and small 
antral follicles (<8 mm), and AMH levels are a more-accurate test of ovarian reserve, as it shows minimal 
intra and inter cycle variation 96. However, concerns have been raised about the lack of universal standards 
for AMH resulting in differences in results based on alternative assays. 
  
The number of ovarian antral follicles (measuring 2–10 mm in diameter) seen in the early follicular phase 
can be measured by TVS. An AFC of ≥12 or ≥20 per ovary when measured using a transvaginal transducer 
with frequencies of 7.5 MHz or 8 MHz, respectively, is used to define polycystic ovarian morphology  67, 84, 
whereas an AFC of ≤10 is suggestive of diminished ovarian reserve 97. A low AFC (3–6 total antral follicles) 
is a predictor of poor response during IVF 98. AMH levels and AFC are good predictors of ovarian response 
to gonadotrophin stimulation during IVF , but are poor at predicting pregnancy 99. 
 
[H2] Screening and prevention 
 
Prior knowledge regarding fertility, levels of anxiety, previous medical history and cultural pressures are 
drivers for health-seeking behaviour. In many countries, social-cultural issues, misconceptions and lack of 
education and/or funds act as barriers and can lead to underestimation of the burden of subfertility 100.  
 
Educational interventions should be directed at improving knowledge of fertility health, which is currently 
modest. Indeed, one large international study surveyed fertility knowledge in 10,045 people from 79 
countries who had been trying to conceive for an average of 2.8 years, and demonstrated an average correct 
score of 57% on a 13-item correct/incorrect scale of risk factors, misconceptions and basic fertility facts 
101. Women should be educated to understand the effects of increasing age on decreasing fertility and 
should be encouraged to check their personal reproductive risk profile 102, with fertility awareness tools to 
facilitate informed choices about their own fertility health  20, 103. Tools are available to provide women with 
personalised fertility guidance such as FertiSTAT. However, as increased knowledge of fertility problems 
can be associated with increased anxiety, particularly in younger men and women, psychological 
approaches are also needed to alleviate possible anxiety caused by fertility information 104, 105. In addition, 
the use of tools tailored to cultural contexts is important to provide education globally  106. 
 
Tubal diseases associated with pelvic infections accounts for up to 35% of female subfertility in many parts 
of the world 107. Screening, early detection and treatment of sexually transmitted diseases, particularly 
chlamydia and gonococcal infections, are important steps in reducing the long-term complications of these 
disorders, such as tubal subfertility. In addition, postpartum and post-miscarriage infections can cause 
tubal damage, and antibiotic prophylaxis should be considered whenever indicated to reduce the risk of 
infections. Genital tuberculosis continues to be a major cause of tubal and uterine factor subfertility in 
regions with high burden of the disease such as South and South East Asia and sub-Saharan Africa  71, 108, 
although the early detection and treatment of this condition helps reduce the risk of damage to 
reproductive organs 109. 
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Addressing exposure to environmental or lifestyle risk factors for subfertility could be used for prevention 
of this disorder. Exposure to several environmental toxins, such as dioxin, certain phthalates, pesticides 
and heavy metals, has been linked to subfertility 110, 111 and whenever possible, exposure to these toxins 
should be avoided. In terms of lifestyle factors, smoking and obesity are associated with subfertility 15. The 
cessation of smoking and the optimization of body weight through health promotion initiatives involving 
increased awareness and availability of support are integral preventive measures for subfertility, but are 
not always effective. Fertility preservation is a key preventive measure in women who require 
chemotherapy and pelvic radiotherapy. In these women, interventions for fertility preservation include 
cryopreservation of oocyte or embryos, GnRH suppression and laparoscopic ovarian transposition 
(surgically moving ovaries out of the radiotherapy field) for those women who require pelvic irradiation. 
A multidisciplinary approach between the treating physician and fertility specialist is key to an effective 
preventive strategy.  
[H1] Management  
The initial management of women with subfertility requires explanation of any identified cause of 
subfertility, the provision of a realistic prognosis (with and without treatment), advice on management 
options (including non-intervention) and provision of information and support  112 (Table 2). The clinician 
should check that all couples are aware of the basic concepts of fertility such as timed intercourse, and 
should provide advice as required on lifestyle factors such as smoking, alcohol consumption and weight 
(Box 2).  
 
[H2] Unexplained subfertility 
 [H3] Expectant management. The likelihood of unassisted pregnancy for women with unexplained 
subfertility can be estimated using a prognostic model, such as the Hunault model, which takes several 
factors into account, including female age, duration of trying to conceive, source of referral (from 
secondary or tertiary care), sperm motility and the occurrence of previous pregnancy regardless of 
outcome 113. For couples with a good prognosis (defined by the Hunault model as ≥30% chance of 
spontaneous conception within 1 year), expectant management is appropriate as many couples will 
conceive without fertility interventions. Indeed, in a prospective cohort study, 60% of women with 
unexplained subfertility achieved pregnancy without treatment within five years  114. However, prognostic 
models do not indicate when couples should stop expectant management in favour of active treatment. In 
addition, the currently available models are limited to prediction at the time of diagnosis, and cannot 
compare the effectiveness of different treatments at multiple points in time 115 . These models do not take 
account of other considerations, such as family size.  
Dutch fertility guidelines recommend 6-12 months of expectant management for couples with a good 
prognosis of spontaneous pregnancy, as defined by the Hunault model 116. This approach was as effective 
as starting medically assisted reproduction immediately, and did not compromise ongoing birth rates, in 
an audit of guideline adherence in 25 clinics  117. By comparison, the 2013 NICE guidance in the United 
Kingdom recommend that IVF is offered to women with unexplained infertility who have not conceived 
after 2 years of regular unprotected sexual intercourse, which can include up to 1 year before their 
fertility investigations, and can be shorter in women >36 years or older  80. 
If expectant management is not effective, or in women with a poor prognosis, options for active 
intervention include hysterosalpingography, intrauterine insemination or IVF, any of which might be the 
next step depending on prognostic factors, patient preference and treatment availability. All treatment 
options require a shared-decision making approach 118. 
 [H3] HSG. HSG is a routine test carried out as part of fertility work-up, but might also have a role in the 
treatment of subfertility. Tubal flushing with an oil-based dye increases pregnancy rates in women with 
normal fallopian tubes (39.7%) , compared with tubal flushing with a water-based dye ( 29.1%), both of 
which are well-tolerated  119, 120. The mechanism of action of HSG on subfertility is not well understood but 
might involve altering the immunological environment in the peritoneal cavity to make it more 
favourable for fertility and/or it may facilitate the passage of oocytes through the fallopian tubes  121. HSG 
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with lipiodol (an oil-based medium) is associated with subclinical hypothyroidism in a proportion of 
women and thyroid function testing is recommended before and after this procedure 122. Whether any 
type of HSG is superior to expectant management in terms of the chances of conceiving naturally is 
unclear owing to lack of evidence. 
 
 [H3] Intrauterine insemination. Intrauterine insemination (IUI) is widely used as a relatively low-cost 
and minimally invasive intervention for unexplained subfertility. Spermatozoa isolated from the ejaculate 
are directly inserted into the uterus at the estimated time of ovulation, either during a natural menstrual 
cycle or after ovarian stimulation using oral medications such as clomiphene citrate and letrozole or 
injectable gonadotropins. However, until recently, this intervention had little supporting evidence 123. 
Three randomised controlled trials (RCTs) have compared IUI to expectant management; two trials 
demonstrated no benefit of IUI  124, 125, although one trial demonstrated a beneficial result. However, the 
positive RCT differed from the other trials as it used ovarian stimulation and included women with an 
unfavourable prognosis and average of four years of infertility (Hunault score <30%). This trial 
demonstrated that three cycles of IUI are more effective than expectant management, with live birth rates 
of 31% and 9%, respectively 126.  
 
 Pelvic inflammatory disease (PID) is a potential complication of IUI, but the average incidence of PID in a 
general population of IUD users is only 1.6 events per 1,000 person years  127. Use of oral ovarian 
stimulation with IUI might be associated with a small increased risk of multiple pregnancy (6%) and, 
rarely, of ovarian hyperstimulation syndrome (OHSS) 123. The 2013 NICE guidance recommends against 
use of IUI 80; however, few clinics use this advice 128, and some evidence suggests that IUI with ovarian 
stimulation is a safe and effective treatment for women with unexplained infertility who have an 
unfavourable prognosis for natural conception. 
 
 [H3] IVF. IVF is a fertility treatment whereby mature oocytes are collected from the ovaries, are fertilized 
by sperm outside the body and the resulting embryo(s) judged to have the best chance of pregnancy are 
introduced directly into the uterus (Figure 7). A related treatment is in vitro maturation (IVM), whereby 
immature oocytes are collected and are matured outside the body. 
 
IVF is the mainstay of treatment for women with tubal disease and men with poor sperm quality, but is 
also frequently used for unexplained subfertility although the evidence supporting the effectiveness of 
IVF in this population is scant. A Cochrane review found no conclusive evidence that IVF is more effective 
than expectant management or IUI with ovarian stimulation, in treatment-naive women with unexplained 
subfertility 129. Five RCTs compared IVF versus IUI with ovarian stimulation. Four of these included 
treatment-naive women and found no evidence of a difference between the two treatments. However, 
one RCT in which all women were pre-treated with IUI and clomiphene demonstrated a higher live birth 
rate in women who proceeded straight to IVF than in women who received further pretreatment with 
gonadotrophins and IUI before IVF .130 Conversely, one small RCT demonstrated a benefit of IVF compared 
with expectant management in extensively pre-treated women, but the birth rate in the expectant 
management arm was very low 131. IVF was more effective than unstimulated IUI 132, 133. 
 
The success rates of IVF are similar regardless of the cause of subfertility. Reporting and comparing data 
about the outcomes of IVF is difficult owing to a lack of universally agreed way of reporting and 
difficulties in accounting for differences between women (for example, age and length of infertility) and 
in the number of embryos transferred. Data from over 144,000 embryo transfer cycles in European 
centres in 2013 (including women with all causes of infertility) reported a clinical pregnancy rate of 
34.5% per embryo transfer 134. Single embryos were transferred in 31% of women, whereas two embryos 
were transferred in 56% of women  134. In Australia and New Zealand in 2016, 87.7% of cycles transferred 
one embryo and the overall clinical pregnancy rate was 33% for cycles that reached embryo transfer 
135. 
 
The treatment pathway for IVF is complex, comprising many steps and decision points; each step has 
alternative clinical approaches, some of which are supported by robust evidence whereas others require 
more research 136 (Supplementary Table 1 and Figure 7). Several factors can hinder the success of IVF or 
can increase the risk of adverse effects, such as smoking, obesity, hydrosalpinx, septate uterus, 
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endometrial polyps and sub-mucosal fibroids, and should be addressed before IVF starts. Some women 
do not respond well to the ovarian stimulation drugs and might be described as ‘poor ovarian 
responders’; however there is little agreement about the definition of “poor response” or the best 
management strategy for these women  137, 138. Single embryo transfer (SET) during IVF reduces the risk 
of multiple pregnancies, and a strategy of successive SETs achieves similar outcomes to double embryo 
transfer but with reduced multiple pregnancy rates 139. Several factors are important for embryo transfer, 
including the use of drug regimens to increase the receptivity of the endometrium, timing of embryo 
transfer, type of transfer catheter and use of ultrasonography for guidance  136 . The retrieval of multiple 
oocytes after ovarian stimulation the cryopreservation of spare embryos and further embryo transfers, 
which could avert the need for repeated ovarian stimulation and oocyte retrieval. Pregnancy outcomes 
similar with frozen embryo transfer and fresh transfer 140.  
In both unassisted pregnancy and IVF cycles, implantation is a key step in achieving pregnancy, and 
accordingly, is often referred to as the ‘rate-limiting step’ 141. If three IVF attempts are unsuccessful, a 
diagnosis of repeated (or recurrent) implantation failure (RIF) is often made  142, 143. However, some data 
suggest that a reliable diagnosis of RIF cannot be made after three IVF cycles, and that diagnosis is likely 
to be more reliable and cost-effective after six IVF cycles, especially in women with a poor prognosis and 
in centres with lower IVF success rates 144 Cohort data support a change to the definition of RIF, as the 
live birth rate associated with the 4th embryo transfer cycle was not significantly different from the rate 
associated with the 3rd cycle  135. Women with RIF can be offered further investigations to establish 
causation, including endometrial receptivity tests, pre-implantation genetic screening, time-lapse imaging 
and immunological tests, but these tests can be invasive and costly. 
 
[H2] Ovulation disorders 
The first line treatment for subfertility in women with PCOS is lifestyle management. Advice can be 
aligned with recommendations that are applicable to the general population, such as obtaining a healthy 
weight, smoking cessation, omitting alcohol, performing exercise and management of mental health 
issues 145. Women with ovulatory disorders who are overweight or obese can be advised to lose weight to 
improve menstrual regularity 146. Indeed, in one RCT a 6-month weight loss intervention increased the 
rate of live births conceived within 24 months in obese women who were anovulatory but not in those 
who were ovulatory  147. A post-hoc analysis demonstrated that among anovulatory women, the likelihood 
of having a live birth conceived within 24 months of the intervention was 40%  147. 
 
If lifestyle management is not effective, women with anovulatory PCOS and no other subfertility factors 
should be offered ovulation stimulation, and should be educated about timed intercourse.. The first line 
ovulation induction drug is letrozole, an oral aromatase inhibitor, and is associated with higher rates of 
ovulation and live births than clomiphene citrate (an oral antioestrogen drug), and possibly with fewer 
multiple pregnancies  145, 148, 149 . If barriers to letrozole use are apparent, such as cost or unavailability, 
other drugs can be used, such as clomiphene citrate, with or without metformin  148, 150. Metformin reduces 
insulin resistance and improves ovulation and pregnancy rates when used in combination with 
clomiphene citrate, in women with PCOS who do not respond to clomiphene alone 67 All women should be 
advised of potential complications associated with ovulation induction agents (such as multiple 
pregnancy). Women should also be advised if the use of such agents is off-label (though permitted) in 
countries where this is the case  145. Women who have achieved regular ovulation with oral induction agents 
can continue this treatment for up to 12 months, as pregnancy and complication rates are acceptable for 
this time period 151. However, prolonged use of ovulation induction agents should be avoided owing to 
low success rates 145  
 
A second-line treatment for women who fail to respond to oral induction agents is gonadotrophins, which 
are injectable drugs 152, . Administration of FSH (a type of gonadotrophin) is associated with higher live 
birth rates than clomiphene citrate (52% versus 41%) but is expensive and requires strict cycle 
monitoring due to the risk of multiple pregnancies. FSH is administered by daily subcutaneous injection 
in a chronic low-dose regimen 153. The addition of IUI to gonadotrophins does not significantly improve 
the chance of conception in women with anovulatory PCOS 152. Preliminary evidence suggests that 
metformin might increase the live birth rate in women undergoing ovulation induction with FSH, 
compared to use of FSH alone 154.  
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A surgical option for ovulation induction is laparoscopic ovarian surgery, which can be offered to women 
with PCOS. No difference in pregnancy rates has been demonstrated between laparoscopic ovarian 
surgery and FSH therapy as second line treatment for women resistant to clomiphene citrate 148. Multiple 
pregnancy rates are markedly decreased following ovarian surgery compared with gonadotrophins 155 . 
When other ovulation induction therapies have failed, women with PCOS and anovulatory infertility can be 
offered IVF as a third-line treatment, in the absence of a clear indication for IVF. However, IVF is usually only 
necessary in women with PCOS who have other factors contributing to subfertility  145 
 
[H2] Fallopian tube disease 
Subfertility associated with tubal adhesions may be treated surgically, ideally using laparoscopic 
techniques to remove adhesions and restore normal anatomy as much as possible. The surgery may be a 
stand-alone procedure, or may precede IVF. The safety and effectiveness of surgery for tubal subfertility 
is unknown, as no randomized studies have been conducted. Tubal surgery is associated with higher 
pregnancy rates in women with mild tubal disease than in those with severe tubal pathology  156. Fertility 
may be restored in women with restored tubal patency, which might allow for more than one live birth to 
occur; however, these women have an increased risk of ectopic pregnancy 157.  
 
Bilateral tubal blockage was the original indication for the use of IVF and is considered a first-line 
intervention for this indication. RCTs are generally considered unnecessary for women with tubal 
subfertility as the majority of women will have complete tubal blockage and no potential alternative 
treatment. Tubal surgery (such as salpingectomy or tubal occlusion) improves IVF success rates in 
women with hydrosalpinges,  158; although the mechanism of action is unknown, it probably involves 
improvement of implantation by reducing inflammation in the genital tract.  
 
 
[H3] Fibroids. The best way to treat fibroids to enhance fertility is controversial. Most clinical guidelines 
recommend hysteroscopic myomectomy for symptomatic fibroids International Federation of 
Gynecology and Obstetrics (FIGO) types 0 and 1 in women seeking to conceive, and this procedure is also 
recommended for asymptomatic fibroids by some guidelines 92. However, a 2015 Cochrane review 
recommended that studies are needed to prove the effectiveness of this intervention 63. A recent review 
suggests that the decision regarding such surgery can be guided by the location, size and number of 
fibroids, and by the availability of clinical expertise and equipment 159 . Research is in progress on medical 
therapies (such as selective progesterone receptor modulators) as an alternative or adjunct to surgery for 
treating fibroids in women seeking fertility, but there is no conclusive evidence in this area 159. 
 
[H3] Endometriosis. For women with minimal or mild endometriosis, excision of the lesions improves 
pregnancy rates in the 9-12 months following surgery (compared with ablation alone), and laparoscopic 
surgery is more effective than diagnostic laparoscopy 160. In women with endometriosis undergoing ART, 
a 3 three month course of GnRH agonist improves pregnancy rates. 160 As ovarian surgery may diminish 
ovarian reserve, the need for surgery should be very carefully considered, especially in the case of 
recurrent endometriosis . There is no good evidence that medical treatment is effective  160.  
 
[H2] POI  
Approximately 5-10% of women with POI have a chance of spontaneous pregnancy, but most will require 
oocyte donation and IVF 161. Oocyte donation involves a woman with good ovarian reserve allowing 
several of her oocytes to be aspirated, following ovarian stimulation during IVF treatment  161. The oocytes 
are then fertilized and the resulting embryos transferred to the uterus of the prospective mother. Oocyte 
donation can also be used for women with ovarian failure following chemotherapy or pelvic radiation. 
 
 
[H1] Quality of life  
Quality of life (QOL) and emotional wellbeing are important considerations for the management of 
subfertility, and supporting women and their partners should be an integral part of fertility care. 
Although fertility clinic staff share this aim, they often lack the resources, such as time and know-how to 
do so 162. Guidelines from the European Society for Human Reproduction & Embryology provides helpful 
tools for clinic staff to optimise patient support (for example, pocket guides, screening tools, patient 
information leaflets and patient administered interventions) 163. 
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The effect of subfertility and associated treatment on wellbeing has been extensively studied using self-
report questionnaires about general health and fertility-specific QoL (e.g., FertiQoL 164) and emotional 
distress (such as anxiety and depression). Subfertility is consistently associated with poorer QOL and 
higher levels of emotional distress compared with population norms and healthy or gynaecological 
controls (typically, women attending gynaecology services for non-fertility reasons)  165-167. In addition, 
the effects of subfertility on emotional distress can persist into pregnancy; women undergoing ARTs 
report more anxiety about fetal viability and health than women with good fertility  168, 169, but have a 
similar rate of postpartum depression 170. Longer-term adjustment to subfertility in longitudinal research 
(> 10 years) shows positive adjustment for most women 171.  
The negative effect of subfertility on wellbeing is principally due to the unfulfilled child wish  171 but also to 
the presence of reproductive disease and treatment. The physical aspects of underlying disorders can be 
stigmatising, painful and emotionally demanding (such as hirsutism and acne in PCOS 172, 173, and severe 
pelvic pain and dyspareunia in endometriosis 174), similar to components of treatment such as ovarian 
stimulation 175, waiting for pregnancy test results 176, and treatment failure 177. Pre-existing psychological 
disorders  178 and coping through avoidance (such as by avoiding pregnant women) can amplify these 
effects, whereas perceived partner and social support can be attenuating 179. 
 
Psychosocial interventions has been recommended to support women with subfertility, but consensus 
about their effect and evaluation has not been reached. The benefits of psychosocial interventions on 
pregnancy (if any) are likely indirect, via treatment uptake. This benefit has been suggested by evidence 
that distressed individuals undergo fewer treatments 180, and meta-analyses have demonstrated that 
emotional distress is not associated with the failure of a single ART cycle 181 but is associated with failure 
in studies with a longer follow-up period 182. Also supportive is the finding that 22% of women 
discontinue treatment before achieving pregnancy  183; the most commonly cited reason for 
discontinuation is the psychological and relationship burden of treatment 184.  
Systematic reviews of QOL studies in individuals with infertility are limited by the fact that most of the 
primary studies include with women undergoing treatment who are from Western countries (in which 
women may be more resilient and have greater support). A review of population studies shows that 
clinical populations represent only ~55% of the infertile population in well-developed (Europe, USA) and 
less well developed (Chile, Gambia, Malawai, India) countries 10. Danish register-based cohort studies 
show that women undergoing ART have a lower rate of depressive disorder  180 and relationship 
dissolution than age-matched population reference groups within five years of starting treatment  167, 
180.Severe social effects, such as social stigma, marital instability and harassment by in-laws are more 
common and consistently reported in reviews of non-Western 185 than Western samples 165, 166.  
 
[H1] Outlook  
 
Alongside efforts to improve established ART techniques, we also support three priorities for future 
research, such as addressing the preventable causes of subfertility, providing support and alternatives for 
individuals with subfertility, and encouraging new initiatives to increase the global accessibility, 
affordability and acceptability of ART  186.  
 
[H2] Subfertility in low-income settings  
A lack of political interest coupled with the high cost of ART has led to a huge gulf between high-income 
and low-income countries in the provision of fertility treatment. In these countries, education, 
prevention, development of low cost interventions and provision of more equitable access to new 
technologies could be achieved 187. 
 
Given the competing priorities for public funding, coupled with the severe effect of childlessness in 
developing countries, significant efforts should focus on prevention of subfertility  185, 188. To this end, 
subfertility might be resolved in low income countries by improved education and utilisation of existing 
resources. However, tubal blockage is very common in some areas 107, 189, most likely secondary to the 
high prevalence of infectious diseases (such as genital tuberculosis and HIV), maternal sepsis, and unsafe 
abortion, and in these cases IVF is often the only treatment option. Despite the global expansion of 
fertility services over the past decade, IVF remains inaccessible in many parts of the world, particularly in 
sub-Saharan Africa 190. New low-cost initiatives are needed to improve the worldwide accessibility, 
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affordability and acceptability of IVF and other subfertility treatments 186. Indeed, simplified techniques 
are being developed to increase the global accessibility of IVF  191-193 and to provide high quality affordable 
centres in low-income countries that integrate subfertility care (including IVF) within family planning  190. 
 
[H2] Improving diagnosis  
Prompt diagnosis of fertility problems is another challenge. One third of women with PCOS had to wait 
for more than two years to reach a diagnosis, and nearly half had been seen by three or more health 
professionals in the process, in one international study. Timely diagnosis of PCOS is important, as this 
facilitates early lifestyle interventions that might prevent subsequent fertility problems 194 There has also been 
a call for early diagnosis of common reproductive disorders such as endometriosis 195 and uterine 
fibroids, 159 though few data are available regarding the benefit on fertility outcomes of earlier diagnosis 
followed by treatment for both conditions. Such conditions often have few or no symptoms to 
differentiate them, and diagnostic tests are expensive or invasive. No longitudinal studies of increased 
surveillance for endometriosis or uterine fibroids have been undertaken, making any recommendations 
about screening or earlier diagnosis difficult to support 66, 92. Accordingly, greater investment in the 
research of the prevalence of these conditions and the value of earlier detection is required. In addition, 
investigation and treatment of non-tubal causes of infertility, such as male infertility, should not be 
overlooked. 
 
[H2] Improving Prevention  
Education is key to preventing subfertility in both high-income and low-income nations, and many young 
adults lack understanding of the potential limitations of their fertility (and its treatment) and how to 
optimize their chance conceiving  101, 104, 196, 197. Indeed, one randomised controlled trial in Japan showed 
accelerated birth timing in 12 months following provision of fertility education compared to healthy 
pregnancy information in partnered individuals  198. Given the steady increase in the median maternal age 
at first birth, future research should address the potential link between fertility knowledge, treatment 
beliefs and planning of parenthood. Public health programmes need to raise awareness of the effects on 
fertility of lifestyle choices, and of practices such as female genital mutilation and consanguineous 
marriage 106. Increased research is required on effective ways to address lifestyle factors that affect 
fertility. In addition, some cases of subfertility could be averted by improved education on STI prevention 
and more comprehensive screening for STIs, including HIV and hepatitis  187. Depending upon local 
prevalence rates, screening should include STIs, in addition to pregnancy or abortion-related infections 
and genital tuberculosis. There has been a call for more research into the pathogens responsible for 
subfertility  199.When subfertility cannot be prevented, more global effort is needed to de-stigmatize 
childlessness, and to support those – mainly women – who find themselves ostracized within societies 
where parenthood is socially mandatory 186, 200 . 
 
[H2] ART  
 [H3] Current ART procedures will continue to improve. Research continues to seek improvements in 
ART outcomes, including better ways to assess embryo and oocyte quality, refinement and 
individualisation of stimulation and triggering protocols, optimizing culture media, improvements in 
ovary, testicular tissue, gamete, and embryo preservation, and techniques for identifying and optimising 
endometrial receptivity 201, 202. Treatments are currently lacking that directly target the age-related 
decline in oocyte quality. 
 
 Many ART clinics around the world are currently offering “add-on” interventions including, time-lapse 
imaging, preimplantation genetic screening, mitochondrial DNA load measurement, and assisted hatching  
203-205 that may be still in the early stages of development, lack clinical evidence of safety and 
effectiveness, and are often costly 205, 206. It could be argued that encouraging women and couples to pay 
for untested and unproven technologies deprives them of the genuine added chance of pregnancy 
associated with having more cycles of conventional treatment 183. In addition, some procedures (such as 
assisted hatching and preimplantation genetic screening) have been offered in routine clinical practice for 
more than a decade despite having have been demonstrated by RCTs as ineffective or even reducing the 
likelihood of pregnancy 205, 206. Thus, it is our view that high quality evidence of the safety and 
effectiveness of ART interventions should precede, not follow, their introduction in routine clinical 
practice. Reproductive medicine will benefit from investment in proper evaluation of current and new 
procedures and finding out what is of true benefit to the patient. 
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 [H3] Safety and ART. ART has several ongoing safety concerns, including the need to reduce multiple 
pregnancies and OHSS, and to ascertain the outcomes of gamete donation and the long term health of the 
mother and offspring. Despite good evidence favouring repeated SET over double embryo transfer, and 
despite improvement in cryopreservation techniques and evidence that frozen transfers are at least as 
good as fresh transfers 139, there has been slow uptake of SET in many parts of the world including China, 
the United States, the United Kingdom and other parts of Europe, and >15% of births following ART are 
still multiple (Figure 8) 207. The UK attempted to improve the uptake of SET by providing a target of <10% 
for multiple pregnancies but this was abandoned in 2013 following a legal challenge  208 . Successful 
strategies to encourage SET uptake have been to provide sufficient funding of ART.If only one IVF cycle is 
funded or if IVF is self-funded, couples might be less likely to accept SET. Countries with good uptake of 
SET (for example, Belgium, Sweden, Australia and New Zealand) have relatively generous IVF state 
funding arrangements and have some of the lowest multiple pregnancy rates (≤5%)  32, 134, 207, 209. To 
reduce the morbidity and mortality of multiple pregnancy rates, governments funding fertility clinics 
need to consider linking the provision of ART with mandatory SET for the first few cycles. The savings in 
neonatal, child and maternal health care would more than offset the provision of IVF 210. 
 
OHSS — a life-threatening complication of ART — has been reducing in prevalence over the past decade, 
owing to a greater recognition of risk factors and improved management options. Hospital admission for OHSS 
is relatively rare (0.4% of stimulated cycles in European countries reporting that information  in 2013) although 
there were three deaths in 2012 and two deaths in 2013 in the European Society of Human Reproduction and 
Embryology report 134. Recommendations for further research include appropriately powered, well-
conducted RCTs to support the current evidence base for interventions to prevent OHSS, including dose-
finding studies and research to determine the optimal timing of interventions  211. 
Increased imprinting disorders have been reported in children conceived though IVF and ICSI although 
there was insufficient evidence of an association between ART and methylation in other imprinted genes  
212. 
 
[H3] Better fertility studies. Long term follow up studies to measure important clinical outcomes in 
mothers who underwent ART and in their offspring, both in childhood and beyond, are needed 213. With 
the exception of national or large longitudinal studies, most IVF monitoring stops shortly after birth  214 
and in clinical trials, simple outcomes such as birthweight are rarely reported 215 and later child outcomes 
are mostly absent 216. Accordingly, the development of a core outcome set for subfertility trials will 
improve reporting 217. 
 
Owing to the increasing use of gamete donation and surrogacy, following the health of donors and the 
resulting children for physical and psychological health is important 218. In some parts of the world, 
notably the United Kingdom, some states in Australia, New Zealand, Netherlands, Sweden and Finland, 
donors can no longer remain anonymous and must consent to the release of their identity if offspring 
request it when they reach 18 years of age. In other regions, no disclosure is required or disclosure is 
prohibited, for example in Spain. In the UK, no children have yet reached the age where they can access 
information themselves: this will be possible in 2023. However, donors and offspring can find each other 
in other ways (such as registers). Positive outcomes have been reported, resulting from donor/offspring 
meetings 219 . A greater understanding about these sometimes complex social issues would be welcome.  
 
[H3] New ART approaches. Radical new approaches in ART include the use of stem cells to create 
oocytes or sperm, the creation of synthetic embryos, gene-editing, prolonged embryo culture, artificial 
gametes, and the development of an artificial uterus. Although these are exciting approaches, careful 
development and evaulation is crucial, as there is a risk that these techniques might progress to clinical 
use without sufficient attention to safety, effectiveness, and their societal and ethical implications 220. A 
large Dutch cross-sectional survey of clinicians, subfertile couples and the general public found that such 
treatments were considered acceptable for six out of eight proposed indications, but that they required 
regulation, preferably by a national bioethics committee  221.  
Responsible implementation of novel techniques is particulary important for reproductive medicine, as 
their effects can potentially affect future generations  221, 222. The example of the widespread enthusiasm to 
introduce add-ons before there was evidence of their effectiveness suggests the need for 
Deleted:   
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greater investment  in evaluative research. The lack of evidence-based medicine for subfertility may be in 
part due to strong beliefs, which are often guided by the commercial interests  of pharmaceutical 
companies, device manufacturers and clinics.  Individuals undertaking fertility treatment are often not 
sufficiently knowledgeable in this regard, and leaders in the field have a responsibility to provide them 
with effective treatments underpinned by quality research. Some individuals have recommended 
that fertility clinics and national and international bodies have a ‘duty of care’ to collect “long term data 
pertaining to the health of any children born as a result of their use”  205 . Furthermore, doctors and 
scientists who recommend an unproven procedure to their patients should provide comprehensive 
information about the lack of evidence on the safety of the intervention on the offspring and “that 
regulatory bodies should require clinical trials to ensure long-term maternal and neonatal follow-up” 205. 
One issue with informed consent, is that a patient could agree to treatment with a technique of unknown 
effectiveness, but that the clinician still remains responsible for what he or she does 223. Unproven 
procedures should only be offered within properly designed trials. 
[H2] Barriers to treatment 
Barriers to fertility care are evident world-wide. Women with subfertility in the United States were more 
likely to receive a medical subfertility evaluation if they were younger, had healthy lifestyle behaviours, a 
male partner with highly educational attainment and state-mandated insurance coverage for subfertility 
treatment  224. Similarly, in the United Kingdom, only 57% of women with subfertility  reported 
seeking any medical or professional help and those with lower incomes were less likely to have sought help 225, 
mirroring the global pattern of infertility medical-help-seeking among subfertile women  10. Other studies have 
reported that greater affordability of ART is associated with greater ART use 226.  
In addition, affordability is also a driver of the use of safer ART practices 227. In women who receive 
interventions for subfertility, many choose to discontinue due to the emotional, relational and physical 
burden of treatment 184. Therefore better care, organization and support for patients should be a priority. 
The recent report of an international commission suggests that the affordability of ART could be 
dramatically improved by the use of cheaper drugs for ovarian stimulation, and simpler laboratory and 
culture systems for IVF and embryo transfer 187 . 
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Box 1. Male subfertility 
 
Male factor infertility is also a cause of subfertility. The male’s contribution to fertility is limited to the 
production of functional spermatozoa that are capable of fertilizing the oocyte. A decrease in motility 
(asthenozoospermia) or abnormal morphology (teratozoospermia) of spermatozoa, in addition to the 
presence of a low number of spermatozoa (oligozoospermia) or the complete absence of spermatozoa in 
the ejaculate (azoospermia) can lower the chance of pregnancy  228.  
Azoospermia can be caused by an obstruction or absence of the vas deferens (obstructive azoospermia), 
or reduced or absent sperm production in the testis (non-obstructive azoospermia). Most men with 
obstructive azoospermia and approximately half of men with non-obstructive azoospermia still have 
residual spermatogenesis in their testes, which allows for surgical retrieval of spermatozoa for 
intracytoplasmic sperm injection and subsequent genetic parenthood  229. If no sperm are available in the 
testis, donor sperm can be used to establish a pregnancy. Men who have non-obstructive azoospermia and who 
also do not produce functional spermatozoa in their testis either have a block in meiosis (maturation arrest), a 
complete absence of germ cells (Sertoli-Cell only syndrome) or a combination of both. Several molecular 
mechanisms underlie maturation arrest, of which, deletions of small or large parts of the Y-chromosome  
are the most common detected cause 230. Such deletions cause the loss of genes that are essential for 
sperm production. Azoospermia can also be an adverse effect of chemotherapy or local radiotherapy. In 
such cases, cryopreservation of ejaculated or surgically retrieved spermatozoa before chemotherapy is 
commonly used to preserve fertility in adult men. In prepubertal boys with cancer in whom spermatozoa 
cannot be cryopreserved before treatment, the surgical retrieval of testicular tissue to allow for future 
fertility restoration using testicular transplants or spermatogonial stem cell transplantation is currently 
under development  231. 
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Box 2. Lifestyle factors and the management of female subfertility.  
 
The likely benefit of a weight loss programme for improving fertility in women is unclear. One systematic 
review of weight loss interventions for treating subfertility 232 included six randomized controlled trials (RCTs) 
reporting pregnancy in subfertile women, and demonstrated a higher rate of pregnancy in women who 
underwent a combination of reducing diet and exercise (54.8%), compared with standard care (49.9%). 
However, live birth rates did not differ significantly between the groups (48.9% versus 46.8%). The largest RCT 
in this systematic review, (which the review authors assessed as having at lowest risk of bias)  included 577 
women with obesity and infertility, and demonstrated that a 6-month weight loss intervention before fertility 
treatment did not increase rates of a vaginal birth of a healthy singleton at term within 24 months, compared 
with immediate IVF  147, 233. In this trial, only 38% of participants achieved their target weight loss and 22% 
discontinued the intervention, and the unassisted pregnancy rate in the intervention group was 26% (versus 16% 
in controls), suggesting some benefit with weight reduction.  
Obese and overweight women with infertility should be encouraged to lose weight, but as no compelling 
evidence supports the use of weight loss to improve live-birth rates in women undergoing IVF, it may be 
advisable to start fertility treatment earlier than previously recommended in women who fail to meet weight 
targets despite their best efforts  234.A healthy weight prior to starting fertility treatment not only improves 
pregnancy outcomes with or without assisted reproductive technologies (ART), but also reduces maternal and 
perinatal complications during pregnancy  234. The long-term health of offspring is also a factor, as maternal 
obesity (that is, a BMI >30kg/m2) is associated with an increased risk of premature death in adult offspring  235. 
No RCTs have been carried out on the effect of on fertility outcomes of smoking cessation or abstinence from 
alcohol. A systematic review of preconception lifestyle advice found a single RCT, which examined the effect 
of advising women with subfertility to stop smoking and found no evidence that this influenced readiness to  
stop smoking. This RCT did not report fertility outcomes  236. However, animal and observational studies 
indicate that cigarette smoking impairs all aspects of fertility in women, including ovarian function, fallopian 
tube function, fertilisation and implantation  237. 
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Figure 1. The female genital tract and factors that affect fertility. Several steps are required for 
conception, including the appropriate development and release of a mature oocyte from the ovaries, 
fertilization by spermatozoa, passage through the fallopian tubes and implantation into the uterus. 
Aberrant development of sperm (including low sperm count, low motility or low number of sperm with 
normal morphology) or oocytes(such as caused by anovulation), or the failure of the sperm to reach and 
fertilize the oocyte (such as due to a blockage, malformation or infection of the female or male genital 
tracts) prevents the generation of an embryo. The embryo can fail to develop during the preimplantation 
stages, implant outside of the uterus (ectopic pregnancy) or fail to implant in the uterus. A receptive 
uterine environment is required for proper embryo implantation and development, including appropriate 
biophysical conditions (such as temperature and pH) and developmental synchrony between a healthy 
embryo and a functionally competent endometrium, and a successful molecular dialogue between the two  
238-241. Consequently, uterine abnormalities or fibroids can finally prevent the implanted embryo to 
develop further. In addition, the cervix needs to be accessible, open and have the right environment to 
allow for passage, activation and capacitation of sperm.The position of the embryo in the genital tract 
during each stage of development is unknown and the timings in this figure are an estimation only.  
 
 
 
Figure 2. The prevalence of primary infertility in 2010 [Au: I’ve edited the title of this figure to 
reduce repetition with the legend, and to ensure that the term ‘primary infertility’ is used herein, 
as this is also used in the original paper - OK?] .  
These data are from women between 20 and 44 years of age with no previous live births, in 2010. A 
demographic definition of infertility was used in this study, which was based on childlessness after 5 years of 
unprotected sexual intercourse. 
Adapted from 3.  
 
Figure 3. Decline in natural fertility with increasing age.  
The decline of the ovarian follicle or oocyte pool with increasing age likely dictates the onset of declining 
fertility, the transition from regular to irregular cycles and the onset of the menopause. Aging is 
associated with a logarithmic decline in the number of ovarian follicles. Simultaneous to a reduction in 
oocyte number with increasing age, there is a decrease in oocyte quality. In this figure, reduced oocyte 
quality is reflected by an increased percentage of embryos with aneuoploidies. Reproduced and adapted 
from de Bruin JP, te Velde ER, in Tulandi and Gosden RG (eds) Preservation of Fertility. London UK. 
Taylor and Francis p3, 2004 and JM Franasiak Fertil Steril. 2014 doi: 10.1016/j.fertnstert.2013.11.004 .  
 
 
 
Figure 4. The ovarian and menstrual cycle  
Follicular stimulating hormone (FSH) is mildly raised at the start of the menstrual cycle and promotes the 
growth of the follicles. Luteinising hormone (LH) rises one to two days after the FSH and in a natural cycle 
ensures ovulation. Progesterone is released following ovulation and rises until the corpus luteum starts 
to degenerate, and has a role in preparing the endometrium for implantation. Estradiol is secreted by 
maturing follicle stimulated by gonadotrophins (FSH and LH). The very high levels at the end of the late 
follicular phase of menstruation are responsible for the LH surge required for ovulation to occur. Basal 
body temperature rises by 0.2 °C approximately 24 hours after ovulation. The endometrium changes from 
the proliferative under the influence of rising estradiol levels to secretory in the post ovulation luteal 
phase under the influence of progesterone and enables implantation. If no pregnancy occurs, then the 
progesterone levels fall and menstruation commences.  
 
Figure 5. Investigations for subfertility.  
 
The baseline investigations for subfertility consist of tests for confirming ovulation and transvaginal 
ultrasonography for female and semen analysis for male partner. Tubal patency tests are advised for 
suspected tubal diseases whereas hormonal tests (for example, serum prolactin, follicle stimulating 
hormone (FSH) and luteinizing hormone (LH) levels) are advised for suspected ovulatory dysfunction. 
For suspected uterine abnormalities, 2D ultrasonography is the first line investigation, whereas women at 
risk of diminished ovarian reserve are offered ovarian reserve tests (e.g. AMH). AFC- antral follicle count; 
AMH- anti mullerian hormone. CAT – chlamydia antibody test; DHEAS – dehydroepiandrostendione 
sulphate; HSG- hysterosalphingography; HyCoSy- hysterosalphino-contrast-sonography; MRI –magnetic 
Commented [AL8]: Please add these two references into 
the list using your reference manager 
 21 
resonance imaging; SIS- saline infusion sonography; TSH- Thyroid stimulating hormone; TFT – thyroid 
function test; TVUS – transvaginal ultrasonography. 
 
Figure 6. Assessment of tubal patency.  
Pelvic images during laparoscopy :A| normal pelvic anatomy. B| Pelvic inflammatory disease with bilateral 
hydrosalpinges (complete tubal blockage). C| Pelvic endometriosis with right ovarian endometrioma and 
adhesions. Adapted from Manual of Gynecological Laparoscopic Surgery. Authors Luca Mencaglia, Arnaud 
Wattiez. Edition illustrated. Publisher Endo-Press, 2006. 
 
Figure 7. IVF procedure. 
Gonadotrophins are given to stimulate the growth of ovarian follicles and gonadotrophin releasing hormone 
(GnRH) agonists are given to suppress the natural menstrual cycle and down-regulate the pituitary gland (step 
1). GnRH antagonists are an alternative to GnRH agonists as they are not associated with hypoestrogenic 
adverse effects, flare-up, or a long down-regulation period and can be used at any time during the follicular 
phase; both regimens have similar live birth rates  242. During the ovulation stimulation phase, regular monitoring 
by ultrasonography (with or without blood tests) is undertaken to assess the growth of the ovarian follicles and 
to avoid ovarian hyperstimulation 243. When the follicles have reached an appropriate size, final maturation of 
the oocytes is induced (ovulation triggering). Human chorionic gonadotropin (hCG) is commonly used as a 
trigger, but can negatively affect endometrial receptivity and embryo quality, and increase rates of ovarian 
hyperstimulation syndrome (OHSS). An alternative, is the agonist trigger which is given if there is an increased 
risk of OHSS. Oocytes are collected, usually with a transvaginal ultrasonography probe for guidance, under 
general or local anaesthetic with sedation (step 2). Oocytes and sperm are combined in a petri dish for 
fertilisation (IVF) or alternatively, intracytoplasmic sperm injection (ISCI) can be used when sperm 
concentration and motility is low (step 3). The fertilised oocyte, now called a preimplantation embryo, is 
cultured for 2-6 days in vitro (step 4). From the pool of available embryos, one (on occasion, two) embryo is 
selected for transfer (step 5). Supernumerary embryos of good quality are cryopreserved and can be thawed and 
transferred one-by-one if pregnancy was not established after fresh embryo transfer or if the couple desires an 
additional child. Drugs such as progesterone or human chorionic gonadotropin are administered for luteal 
support, to improve the likelihood of implantation and pregnancy and are usually stopped at 12 weeks’ gestation  
244.  
 
Figure 8. SET and birth outcomes.  
The proportion of assisted reproductive technology (ART) cycles using single embryo transfer (SET) has 
increased since 2004 (not shown); during the same timeframe, the multiple pregnancy rate has reduced. 
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Table 1. WHO classification of anovulationa  
 
 
WHO 
classification 
Cause 
Examples Hormonal alteration 
Type I Hypothalamic-
pituitary failure 
 
Low body 
weight, 
Excessive 
exercise 
Low levels of circulating 
gonadotropins and serum estradiol  
Type II Hypothalamic -
pituitary – ovarian 
axis dysfunction  
Polycystic 
ovarian 
syndrome 
Normal levels of circulating 
gonadotropins and serum estradiol  
Type III Ovarian failure Premature 
ovarian failure 
High levels of circulating 
gonadotrophin and low levels of 
serum estradiol 
a Advances in methods of fertility regulation: report of a WHO scientific group. World Health Organization 
technical report series 527, 1 (1973)
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Table 2: Options for fertility treatments [Au: references for display items need to be included in the main reference list; as all of the references in this 
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Category Unexplained infertility Anovulation or PCOS Tubal Factors, 
Endometriosis or 
Fibroids 
Advanced age , diminished 
ovarian reserve and POI 
Early 
management 
options 
 
Use a locally applicable 
prediction model for 
natural conception  
E.g. (using Hunault model 113   
) 
If prediction score ≥30%, then 
continue trying for 
unassisted pregnancy for up 
to 3yrs plus risk reduction 20 
[Au: ref OK? See Janes 
comment  I THINK THIS IS 
THE WRONG REF AND 
THAT IT IS 113]   
If prediction score <30% then 
consider 3 cycles of 
intrauterine insemination with 
oral ovarian stimulation 126 
[Au: ref OK?] .  
 
Ovulation induction 
with oral agents (up to 
12 cycles) 151 [Au: ref 
OK?]  
 
 
Fibroids 
 Merits of surgery are 
uncertain. Consider 
hysteroscopic 
myomectomy  63, 92   
[Au: refs OK?]  
 More severe disease: 
Fertility outcomes 
uncertain: decide 
about surgery on 
considerations of pain 
rather than fertility  92 
[Au: ref OK?]  
 
Endometriosis 
 Minimal disease: 
surgical excision of 
lesions  160. [Au: ref 
OK?]  
 If undergoing ART, 
pretreat with 3 months 
of GnRH agonist 160. 
[Au: ref OK?]  
N/A  
 Second line 
early 
management 
options  
 N/A  Ovulation 
induction 
with 
gonadotroph
in 151 [Au: ref 
OK?]  
 N/A  N/A  
Commented [JB9]: Reference 9 was a linked 
recommendation when advised to continue trying for 
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GnRH, gonadotropin-releasing hormone; IVF; in-vitro fertilization; PCOS, polycystic ovarian syndrome. POI, primary ovarian insufficiency; WES World 
Endometriosis Society EFI Endometriosis Fertility Index. (Johnson et al 2017) 
Prediction model https://www.freya.nl/probability.php 
 
 
 
 Laparoscopi
c ovarian 
drilling for 
women who 
do not 
ovulate at 
maximum 
daily dose of 
clomiphene 
citrate 155 
[Au: ref 
OK?]  
Assisted 
Reproduction 
IVF IVF (third-line) 145[Au: 
ref OK?] 
IVF with and without GnRH 
analogues 
 Advanced age or 
diminished 
ovarian reserve : 
IVF 
 
 POI : Oocyte or  
 embryo donation  161 [Au: 
ref OK?]  
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